NATCO

Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

15th May, 2026

Corporate Relationship Department
M/s. BSE Limited
Mumbai 400001
Scrip Code: 524816

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Bandra (E) Mumbai 400051
Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Ref : Disclosure under Regulation 30 of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 submitted vide letter dated 14.05.2026

With reference to the above cited subject, we would like to inform you that the Company has received a Demand notice dated 12th May, 2026 from National Pharmaceutical Pricing Authority. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with read with SEBI's Circular No. **SEBI/HO/CFD/PoD2/CIR/P/0155** dated November 11, 2024 and SEBI Master Circular No.**HO/49/14/14(7)2025-CFD-POD2/I/3762/2026** updated on January 30, 2026 are as under:

S. No.	**Particulars**	**Information**
1.	Name of the Authority	National Pharmaceutical Pricing Authority, New Delhi
2.	Nature and details of the action(s) taken or order(s) passed	Demand Notice issued under para 15 of Drugs Price Control Order, 2013 ("DPCO"), directing the Company to deposit an amount of ₹ 4,92,25,923/- (which includes overcharge amount, penalty and interest)
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Demand notice received on 12th May, 2026
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Demand notice alleges overcharging for 2 drugs covering period between April-2023 to November-2023
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on financial, operational and other activities of the Company
6.	Reason for delay	We wish to inform you that there was delay in submission of disclosure due to technical issues/procedural delay in flow of information. The Company has since complied with the disclosure requirements of SEBI (LODR) Regulations, 2015 and submitted the necessary information to stock exchanges. Further, we shall take necessary steps to avoid recurrence of such delays in future.

This is for your information and records.

Thanking you,
Yours faithfully,
For NATCO Pharma Limited

VENKAT RAMESH CHEKURI
Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.05.15 11:41:41 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer